Skip to content
TrialScanner

NCT07083479

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

No phase registeredNo longer availableELTXLead

Registry record

Lead sponsor
Elicio Therapeutics
Conditions
Pancreatic Ductal Adenocarcinoma; KRAS G12D; KRAS G12V; KRAS G12S; KRAS G12A
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07083479 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07083479: Expanded Access Protocol of... | TrialScanner